Table 5.
Treatment-related adverse events reported in the single- and multiple-dose CMAB008 groups
| Single-dose groups
|
Multiple-dose group
|
|||
|---|---|---|---|---|
| 1 mg/kg (n=9) | 3 mg/kg (n=9) | 10 mg/kg (n=9) | 3 mg/kg (n=9) | |
| Any | 1 (11.1) | 0 | 7 (77.8) | 2 (22.2) |
| Dizziness | 0 | 0 | 4 (44.4) | 0 |
| Muscular soreness | 0 | 0 | 3 (33.3) | 0 |
| Pyrexia | 0 | 0 | 1 (11.1) | 0 |
| Abdominal pain | 0 | 0 | 1 (11.1) | 0 |
| Diarrhea | 0 | 0 | 1 (11.1) | 0 |
| Colds | 0 | 0 | 1 (11.1) | 0 |
| Nausea | 0 | 0 | 0 | 1 (11.1) |
| Genital herpes | 1 (11.1) | 0 | 0 | 0 |
| ALT and AST increase | 0 | 0 | 1 (11.1) | 0 |
| RBC decrease | 0 | 0 | 0 | 1 (11.1) |
| WBC decrease | 0 | 0 | 0 | 1 (11.1) |
| Hb decrease | 0 | 0 | 0 | 1 (11.1) |
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; RBC, red blood cell; WBC, white blood cell.